CYC cyclopharm limited

Bell Potter rates ((CYC)) as Buy

  1. 859 Posts.
    lightbulb Created with Sketch. 118

    03/06/20

    Bell Potter rates ((CYC)) as Buy (1) –

    Cyclopharm has taken steps towards getting regulatory approval from the US, filing for a 505(b)2 registration for Technegas.

    Technegas is helpful for diagnosing covid-19 patients with acute respiratory distress syndrome and aids in understanding how much a patient’s respiratory has been impacted.

    The company raised $9.7m in December 2019 with the funds used to establish US operations later this year. Revenue estimates have been reduced for FY20-21 due to delay in launching the US operations.

    Bell Potter leaves the rating unchanged at Buy along with an unchanged target of $1.77.

    Last edited by pforpaul: 04/06/20
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
81.0¢
Change
0.040(5.19%)
Mkt cap ! $90.02M
Open High Low Value Volume
78.0¢ 81.0¢ 78.0¢ $82.65K 105.2K

Buyers (Bids)

No. Vol. Price($)
1 58 79.5¢
 

Sellers (Offers)

Price($) Vol. No.
81.5¢ 504 3
View Market Depth
Last trade - 12.44pm 12/09/2025 (20 minute delay) ?
CYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.